Pin1 expression contributes to lung cancer Prognosis and carcinogenesis

Cancer Biology and Therapy

Volumn 9, Issue 2, 2010, Pages 111-119

  Tan, Xiaogang ^a   Zhou, Fang ^a   Wan, Junting ^a   Hang, Jie ^a   Chen, Zhaoli ^a   Li, Baozhong ^a   Zhang, Cuiyan ^a   Shao, Kang ^a   Jiang, Peng ^c   Shi, Susheng ^b   Feng, Xiaoli ^b   Lv, Ning ^b   Wang, Zhen ^a   Ling, Yun ^a   Zhao, Xiaohong ^a   Ding, Dapeng ^a   Sun, Jian ^a   Xiong, Meihua ^a   He, Jie ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

Carcinogenesis; NSCLC; Pin1; Prognosis

Indexed keywords

GLYCOGEN; PEPTIDYLPROLYL ISOMERASE PIN1; SMALL INTERFERING RNA; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; TUMOR PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CELL ANCHORAGE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CIGARETTE SMOKING; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; ANIMAL; BIOSYNTHESIS; CANCER INVASION; CANCER TRANSPLANTATION; CELL MOTION; CELL TRANSFORMATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL; TRANSPLANTATION; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PEPTIDYLPROLYL ISOMERASE; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TUMOR STEM CELL ASSAY;

EID: 75749088527     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.2.10341     Document Type: Article

References (33)

1. Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffe CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000; 92:1717-30.
2. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996; 380:544-7.
3. Lu KP. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 2004; 29:200-9.
4. Wulf G, Garg P, Liou YC, Iglehart D, Lu KP. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 2004; 23:3397-407.
5. Lim J, Lu KP. Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 2005; 1739:311-22.
6. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17:215-24.
7. Brondani V, Schefer Q, Hamy F, Klimkait T. The peptidyl-prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor alpha stability. Biochem Biophys Res Commun 2005; 328:6-13.
8. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001; 20:3459-72.
9. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, Wang DG. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004; 164:1727-37.
10. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003; 63:6244-51.
11. Ryo A, Uemura H, Ishiguro H, Saitoh T, Yamaguchi A, Lu KP, et al. Stable suppression of tumorigenicity by Pin1-targeted rna interference in prostate cancer. Clin Cancer Res 2005; 11:7523-31.
12. Pang RW, Lee TK, Man K, Poon RT, Fan ST, Kwong YL, et al. PIN1 expression contributes to hepatic carcinogenesis. The Journal of pathology 2006; 210:19-25.
13. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003; 63:6244-51.
14. Miyashita H, Uchida T, Mori S, Echigo S, Motegi K. Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with Cycline D1 mRNA expression and clinical significance of cyclins. Oncol Rep 2003; 10:1045-8.
15. He J, Zhou F, Shao K, et al. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer 2007; 56:51-8.
16. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008; 105:4826-31.
17. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 2007; 253:236-48.
18. Strauss GM, Herndon J, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) Protocol 9633. J Clin Oncol 2006; 24:365.
19. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-21.
20. Winton T, Livingston R, Johnson D, Joenson D, Rigas J, Johnstone M, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-97.
21. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, et al. Adjuvant vinorelbin and cisplatin versus observation in completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine Intenational Trialist Association [ANITA]): a randamised controlled trial. Lancet Oncol 2006; 7:719-27.
22. The International Adjuvant Lung Cancer Trial Collaborative Group, Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350:351-60.
23. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. Cancer J Clin 2003; 53:5-26.
24. Beer DG, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-24.
25. Potti A, Mukherjee S, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355:570-80.
26. Chen HY, Yu SL, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11-20.
27. Bianchi F, Nuciforo P, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117:3436-44.
28. Uchida T, Takamiya M, Takahashi M, et al. Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem Biol 2003; 10:15-24.
29. Miyashita H, Uchida T, Mori S, et al. Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with Cycline D1 mRNA expression and clinical significance of cyclins. Oncol Rep 2003; 10:1045-8.
30. Rippmann JF, Hobbie S, Daiber C, et al. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ 2000; 11:409-16.
31. Clark RA. Biology of dermal wound repair. Dermatol Clin 1993; 11:647-66.
32. Ryo A, Liou YC, Lu KP, Wulf G. Prolylisomerase Pin1: a catalyst for oncogenesis and apotential therapeutic target in cancer. J Cell Sci 2003; 116:773-83.
33. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP. PIN1 is an E2F target gene essential for Neu/Rasinduced transformation of mammary epithelial cells. Mol Cell Biol 2002; 22:5281-95.